LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

Search

Celldex Therapeutics Inc

Fechado

SetorSaúde

29.87 -3.99

Visão Geral

Variação de preço das ações

24h

Atual

Mín

29.28

Máximo

31.22

Indicadores-chave

By Trading Economics

Rendimento

-14M

-81M

Vendas

75K

75K

EPS

-1.22

Margem de lucro

-108,422.667

Funcionários

198

EBITDA

-7.8M

-81M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+75.79% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

430M

2B

Abertura anterior

33.86

Fecho anterior

29.87

Sentimento de Notícias

By Acuity

50%

50%

153 / 351 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de mar. de 2026, 23:12 UTC

Ações em Alta

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12 de mar. de 2026, 22:15 UTC

Ganhos

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12 de mar. de 2026, 21:42 UTC

Notícias Principais

Stryker Says Cyberattack Disruption Is Continuing

12 de mar. de 2026, 21:29 UTC

Notícias Principais

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12 de mar. de 2026, 21:27 UTC

Ganhos

Adobe CEO to Depart as AI Boosts Sales -- Update

12 de mar. de 2026, 20:46 UTC

Ganhos

Adobe Posts Higher Sales With CEO Set to Depart

12 de mar. de 2026, 20:21 UTC

Notícias Principais

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12 de mar. de 2026, 23:57 UTC

Conversa de Mercado

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12 de mar. de 2026, 23:38 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 de mar. de 2026, 23:38 UTC

Conversa de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12 de mar. de 2026, 22:13 UTC

Ganhos

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12 de mar. de 2026, 22:13 UTC

Ganhos

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12 de mar. de 2026, 22:13 UTC

Ganhos

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12 de mar. de 2026, 22:13 UTC

Ganhos

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12 de mar. de 2026, 22:13 UTC

Ganhos

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12 de mar. de 2026, 22:13 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

12 de mar. de 2026, 22:13 UTC

Conversa de Mercado
Ganhos

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12 de mar. de 2026, 21:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12 de mar. de 2026, 21:04 UTC

Ganhos

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12 de mar. de 2026, 21:02 UTC

Ganhos

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12 de mar. de 2026, 21:02 UTC

Ganhos

Wheaton Precious Metals 4Q Sales $865M >WPM

12 de mar. de 2026, 21:02 UTC

Ganhos

Wheaton Precious Metals 4Q Net $558.3M >WPM

12 de mar. de 2026, 21:02 UTC

Ganhos

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12 de mar. de 2026, 20:57 UTC

Conversa de Mercado
Notícias Principais

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

12 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de mar. de 2026, 20:15 UTC

Aquisições, Fusões, Aquisições de Empresas

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12 de mar. de 2026, 20:10 UTC

Ganhos

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12 de mar. de 2026, 20:05 UTC

Ganhos

Adobe 1Q Rev $6.4B >ADBE

12 de mar. de 2026, 20:05 UTC

Ganhos

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

75.79% parte superior

Previsão para 12 meses

Média 54.9 USD  75.79%

Máximo 90 USD

Mínimo 24 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

9

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

153 / 351 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat